| Primary |
| Product Used For Unknown Indication |
35.5% |
| Malignant Melanoma |
24.0% |
| Metastatic Malignant Melanoma |
22.2% |
| Pain |
4.0% |
| Hypertension |
3.5% |
| Neoplasm Malignant |
2.1% |
| Nausea |
1.0% |
| Depression |
0.9% |
| Prophylaxis |
0.9% |
| Diabetes Mellitus |
0.7% |
| Anxiety |
0.7% |
| Constipation |
0.6% |
| Insomnia |
0.6% |
| Malignant Melanoma Stage Iv |
0.6% |
| Hypothyroidism |
0.6% |
| Metastases To Central Nervous System |
0.5% |
| Atrial Fibrillation |
0.4% |
| Convulsion |
0.4% |
| Rash |
0.4% |
| Skin Cancer |
0.4% |
|
| Death |
39.3% |
| Disease Progression |
15.0% |
| Rash |
6.9% |
| Fatigue |
3.7% |
| Weight Decreased |
3.7% |
| Vomiting |
3.2% |
| Malignant Melanoma |
3.0% |
| Arthralgia |
2.6% |
| Metastases To Central Nervous System |
2.6% |
| Metastatic Malignant Melanoma |
2.2% |
| Neoplasm |
2.2% |
| Sunburn |
2.1% |
| Pyrexia |
2.0% |
| Renal Failure |
1.9% |
| Photosensitivity Reaction |
1.7% |
| Renal Failure Acute |
1.6% |
| Squamous Cell Carcinoma |
1.6% |
| Dysphagia |
1.6% |
| Nausea |
1.6% |
| Skin Papilloma |
1.6% |
|
| Secondary |
| Metastatic Malignant Melanoma |
24.6% |
| Malignant Melanoma |
20.4% |
| Prophylaxis |
12.1% |
| Product Used For Unknown Indication |
9.3% |
| Pain |
4.9% |
| Essential Hypertension |
4.4% |
| Hypertension |
3.2% |
| Insomnia |
2.8% |
| Diarrhoea |
2.4% |
| Thyroid Cancer |
2.3% |
| Thyroidectomy |
2.2% |
| Breast Cancer Metastatic |
1.9% |
| Hypothyroidism |
1.8% |
| Depression |
1.4% |
| Nausea |
1.4% |
| Neoplasm Malignant |
1.2% |
| Epilepsy |
1.1% |
| Arthralgia |
1.0% |
| Metastases To Central Nervous System |
1.0% |
| Anticoagulant Therapy |
0.8% |
|
| Weight Decreased |
15.0% |
| Death |
12.4% |
| Fatigue |
8.6% |
| Rash |
8.6% |
| Vomiting |
5.6% |
| Blood Creatinine Increased |
4.9% |
| Blood Uric Acid Increased |
4.5% |
| Rash Generalised |
4.1% |
| Nausea |
3.8% |
| Sunburn |
3.4% |
| Arthralgia |
3.0% |
| Renal Failure |
3.0% |
| Squamous Cell Carcinoma Of Skin |
3.0% |
| Swelling Face |
3.0% |
| Thrombocytopenia |
3.0% |
| Tumour Lysis Syndrome |
3.0% |
| Visual Impairment |
3.0% |
| Diarrhoea |
2.6% |
| Renal Failure Acute |
2.6% |
| Skin Papilloma |
2.6% |
|
| Concomitant |
| Epilepsy |
19.4% |
| Metastatic Malignant Melanoma |
16.1% |
| Malignant Melanoma |
9.7% |
| Neoplasm Malignant |
6.5% |
| Skin Cancer |
6.5% |
| Back Pain |
3.2% |
| Brain Oedema |
3.2% |
| Convulsion |
3.2% |
| Depression |
3.2% |
| Metastasis |
3.2% |
| Multiple Myeloma |
3.2% |
| Myocardial Infarction |
3.2% |
| Nausea |
3.2% |
| Nuclear Magnetic Resonance Imaging Brain |
3.2% |
| Osteoporosis |
3.2% |
| Pain |
3.2% |
| Polycythaemia Vera |
3.2% |
| Product Used For Unknown Indication |
3.2% |
|
| Weight Decreased |
16.7% |
| Death |
8.3% |
| Hot Flush |
8.3% |
| Lethargy |
8.3% |
| Livedo Reticularis |
8.3% |
| Malignant Melanoma |
8.3% |
| Off Label Use |
8.3% |
| Partial Seizures |
8.3% |
| Sudden Death |
8.3% |
| Swelling |
8.3% |
| Thrombocytopenia |
8.3% |
|
| Interacting |
| Malignant Melanoma |
33.3% |
| Metastatic Malignant Melanoma |
16.7% |
| Nervous System Disorder |
16.7% |
| Oral Candidiasis |
16.7% |
| Convulsion |
8.3% |
| Gastrooesophageal Reflux Disease |
8.3% |
|
| Drug Interaction |
33.3% |
| Neutropenia |
33.3% |
| Skin Toxicity |
16.7% |
| Squamous Cell Carcinoma |
16.7% |
|
